Antipsychotic Dosing and Management
Start antipsychotics at the lowest licensed/effective dose and titrate upward based on therapeutic response, aiming for approximately 5 mg/day risperidone equivalents for maximal efficacy in schizophrenia, with assessment of response at 4 weeks. 1, 2
Starting Doses and Titration
The most recent international guidelines emphasize a low-dose start strategy 1. Begin with the lowest effective dose and gradually increase based on tolerability and response. The dose-response curve for antipsychotics follows a hyperbolic pattern, meaning efficacy plateaus relatively quickly—around 5 mg/day risperidone equivalents represents the maximally efficacious average dose 2.
Key titration principles:
- Assess therapeutic effectiveness at 4 weeks minimum at a therapeutic dose with confirmed adherence 1
- Consider once-daily dosing at night when possible to improve adherence 2
- Titrate based on half-life and receptor profile of the specific medication 1
- For clozapine specifically: titrate to achieve plasma levels of at least 350 ng/mL; if inadequate response at 12 weeks, may increase to 550 ng/mL 1
Common Pitfall to Avoid
Many clinicians use doses higher than necessary. The evidence shows that supersaturating D2 receptors (going beyond ~5 mg risperidone equivalents) increases adverse effects without improving efficacy 2, 3. Resist the temptation to rapidly escalate doses in non-responders—instead, switch medications after an adequate 4-week trial 1.
Switching Strategies
When switching antipsychotics due to inadequate response or tolerability issues, use gradual cross-titration rather than abrupt switches 1, 4. This prevents dopamine rebound phenomena that occur when dopamine blockade isn't kept relatively constant.
Switching algorithm:
- Choose a medication with a different pharmacodynamic profile than the failed agent 1
- Use overlapping "plateau" strategies where both medications are briefly co-administered 4
- Account for half-life differences—switching from short to long half-life drugs requires particular caution 4
- Consider transient benzodiazepines to manage rebound agitation during the switch 4
If switching from a D2 partial agonist, consider amisulpride, risperidone, paliperidone, or olanzapine (with metformin) as second-line 1.
Treatment-Resistant Schizophrenia
After failure of two different antipsychotics (each tried for 4 weeks at therapeutic doses with good adherence), initiate clozapine 1, 5. This is a Level 1B recommendation from the APA 5. All 17 guidelines reviewed endorsed clozapine after two failed trials 6.
Always co-prescribe metformin with clozapine to attenuate weight gain 1. For clozapine plasma concentrations above 550 ng/mL (which have diminishing returns with NNT=17), consider prophylactic lamotrigine due to seizure risk 1.
Side Effect Management
Extrapyramidal Symptoms (EPS)
Acute dystonia: Treat immediately with anticholinergic medication (Level 1C recommendation) 5
Parkinsonism: Three options in order of preference 5:
- Lower the antipsychotic dose
- Switch to another antipsychotic with lower EPS risk
- Add anticholinergic medication
Akathisia: Four management options 5:
- Lower the dose
- Switch antipsychotics
- Add a benzodiazepine
- Add a beta-blocker
Tardive Dyskinesia
For moderate to severe or disabling tardive dyskinesia, treat with a VMAT2 inhibitor (valbenazine or deutetrabenazine)—this is a Level 1B recommendation 5. Note that the clinical utility of these newer agents is still being established 7.
Metabolic Side Effects
Weight gain and metabolic syndrome:
- Metformin is the most evidence-based intervention, producing slight to moderate weight loss 7
- Metformin should be offered proactively with clozapine and olanzapine 1
- Standard medications are effective for managing dyslipidemia and hyperglycemia 7
Other Common Side Effects
Sialorrhea (excessive salivation): Anticholinergic drops applied sublingually 7
Constipation: Standard laxative medications 7
Sexual dysfunction: Consider dose reduction or switching to an antipsychotic with lower prolactin elevation (e.g., aripiprazole, quetiapine) 7
Special Populations
First episode psychosis: Evidence suggests approximately one-third dose reduction compared to multi-episode patients 3. Studies with risperidone and haloperidol support this lower dosing approach.
Elderly patients: Start lower and titrate more slowly due to decreased pharmacokinetic clearance, increased risk of QTc prolongation, stroke, and mortality (particularly in dementia-related psychosis) 3.
Acute agitation: Intramuscular formulations are often used, but avoid supersaturating doses despite the urgency—they increase adverse effects without improving efficacy 3.
Adherence Optimization
Consider long-acting injectable (LAI) formulations if the patient prefers them or has a history of poor/uncertain adherence (Level 2B suggestion) 5. Once-daily dosing at night improves adherence for oral formulations 2.
Plasma level monitoring helps detect non-adherence and is particularly useful for clozapine dose optimization 1, 2.
Critical Decision Points
The distinction between "first-generation" and "second-generation" antipsychotics is neither pharmacologically valid nor clinically useful 1, 2. Instead, select medications based on:
- Individual receptor binding profiles
- Side effect profiles (which are more objectively measurable than efficacy differences) 2
- Previous response in the patient's illness history
- Available formulations (oral, LAI)
- Metabolism and half-life characteristics 1
Computer applications are now available to facilitate evidence-based selection between antipsychotics based on these parameters 2.